The latest wave of artificial intelligence (AI), digital health, and Direct-to-Patient (DTP) models have the potential to drive significant innovation, transform patient experiences, and redefine business and operating models across life science companies. Estimates show that AI alone could drive value equivalent to 11% of current revenue for a typical pharma company. Plus, DTP models, including digital health, could create $100 billion in annual value through improved engagement, prescription fulfillment, adherence, and retention. But to fully unlock these massive opportunities, life science companies must embrace a new way of operating and measuring success.
Scott Snyder, Chief Digital Officer at EVERSANA, recently authored an article in Pharmaceutical Commerce about how the industry is changing its operating model to incorporate AI.
“The future of the pharma industry lies in embracing AI and direct-to-patient models to drive innovation and enhance patient experiences”
– Scott Snyder, Chief Digital Officer
Read the full article on Pharmaceutical Commerce here: Measuring What Matters
Connect With An Expert!
Author
Scott serves as EVERSANA’s Chief Digital Officer, driving digital transformation for employees, clients, and the patients we serve. He brings more than 30 years of experience in emerging technologies and digital transformation across both…